Description

Etruzil (letrozole) Coated Tablets 2.5 mg. №30

Ingredients

Active ingredient: Letrozole 2.5 mg.
Inactive ingredients: lactose monohydrate, maize starch, colloidal anhydrous silica, magnesium stearate, hypromellose, macrogol 6000, titanium dioxide (E171).

Dosage

Recommended dosage: The usual dose is one 2.5 mg tablet daily, with or without food, or as directed by a healthcare professional.

Indications

Etruzil (letrozole) coated tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.

Contraindications

Do not use Etruzil (letrozole) coated tablets if you are allergic to letrozole or any of the inactive ingredients. It is contraindicated in premenopausal women.

Directions

Take Etruzil (letrozole) coated tablets exactly as prescribed by your healthcare provider. Swallow the tablet whole with a glass of water.

Scientific Evidence

Letrozole, the active ingredient in Etruzil, is an aromatase inhibitor that works by reducing estrogen levels in postmenopausal women, thereby inhibiting the growth of hormone-sensitive breast cancer cells. Clinical trials have shown that letrozole is effective in reducing the risk of cancer recurrence in postmenopausal women with early-stage breast cancer.

Additional Information

It is important to discuss with your healthcare provider about the potential benefits and risks of using Etruzil (letrozole) coated tablets. Regular monitoring and follow-up are crucial during the treatment period.

Pharmacological Effects

Letrozole inhibits the aromatase enzyme, which is responsible for the conversion of androgens to estrogens. By blocking estrogen production, letrozole helps in suppressing tumor growth in hormone-sensitive breast cancer. This mechanism makes it a valuable adjuvant therapy in postmenopausal women with breast cancer.

Clinical Trials and Comparative Effectiveness

Several clinical trials have demonstrated the efficacy of letrozole in improving disease-free survival and reducing the risk of cancer recurrence compared to tamoxifen in postmenopausal women with early-stage breast cancer. Letrozole has shown superior effectiveness and tolerability profiles in comparison to other aromatase inhibitors, making it a preferred choice in adjuvant therapy.

References:
1. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349(19):1793-1802.
2. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 2001;19(10):2596-2606.